DENISE RICIGLIANO: Open Payments
NPI 1073763835 · SALINAS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,165 in 23 payments from 11 companies in 2025. Trend: 2023 $5,996 · 2024 $859 · 2025 $1,165
Food & beverage: $1,165
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 2 | $261 |
| Merck Sharp & Dohme LLC | 5 | $145 |
| GlaxoSmithKline, LLC. | 3 | $140 |
| Daiichi Sankyo Inc. | 5 | $139 |
| Myriad Genetic Laboratories, Inc. | 1 | $126 |
| Stemline Therapeutics Inc. | 1 | $123 |
| Exelixis Inc. | 1 | $112 |
| ABBVIE INC. | 2 | $42 |
| AstraZeneca Pharmaceuticals LP | 1 | $29 |
| Karyopharm Therapeutics Inc. | 1 | $29 |
Products named: TECVAYLI, KEYTRUDA, PRECISETUMOR, Orserdu, CABOMETYX, RYBREVANT, OJJAARA, ENHERTU.
Industry payments across CA — which companies pay providers there.
